Admission blood tests predicting survival of SARS-CoV-2 infected patients: a practical implementation of graph convolution network in imbalance dataset.

Journal: BMC infectious diseases
PMID:

Abstract

BACKGROUND: Predicting an individual's risk of death from COVID-19 is essential for planning and optimising resources. However, since the real-world mortality rate is relatively low, particularly in places like Hong Kong, this makes building an accurate prediction model difficult due to the imbalanced nature of the dataset. This study introduces an innovative application of graph convolutional networks (GCNs) to predict COVID-19 patient survival using a highly imbalanced dataset. Unlike traditional models, GCNs leverage structural relationships within the data, enhancing predictive accuracy and robustness. By integrating demographic and laboratory data into a GCN framework, our approach addresses class imbalance and demonstrates significant improvements in prediction accuracy.

Authors

  • Jie Lian
    Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Fan Huang
  • Xinhai Huang
    Faculty of Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  • Kitty Yu-Yeung Lau
    Biomedical Engineering Programme, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Kei Shing Ng
    Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  • Carlin Chun Fai Chu
    Department of Computing, The Hang Seng University of Hong Kong, Shatin, Hong Kong SAR, China.
  • Simon Ching Lam
    School of Nursing, Tung Wah College, Ho Man Tin, Hong Kong SAR, China.
  • Mohamad Koohli-Moghadam
    Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  • Varut Vardhanabhuti
    Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.